...
首页> 外文期刊>Breast cancer research and treatment. >The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer
【24h】

The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer

机译:内质网应激标志物GRP78和CHOP预测乳腺癌的无病生存期和对化疗的反应性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Glucose-regulated protein (GRP) 78 and C/-EBP homologous protein (CHOP) are commonly used as markers of endoplasmic reticulum (ER) stress. As an ER chaperone, GRP78 functions as a potent anti-apoptotic factor and confers drug resistance, whereas CHOP is a key initiating factor of ER stress-related cell death. We aimed at investigating the predictive values of GRP78 and CHOP in breast cancer patients who underwent adjuvant chemotherapy. An immunohistochemistry screen for GRP78 and CHOP was performed using a tissue microarray containing 250 tumors from female patients diagnosed with invasive ductal breast carcinoma at the Fudan University Shanghai Cancer Center. The staining results were scored semi-quantitatively, and a prediction model was constructed to verify the hypothesis. In this retrospective cohort study, CHOP correlated with prolonged disease-free survival (HR = 0.385, 95 % CI 0.215-0.688; P = 0.001), whereas GRP78 showed an opposite association (HR = 4.573; 95 % CI 2.291-9.128; P < 0.001). Moreover, in a GRP78-positive subset, CHOP overexpression correlated with a lower risk of recurrence. In the receiver operating characteristic analysis, the prediction capability of the predictive model combining the above two markers surpassed that of the traditional model (P = 0.0085 for the area under the curve comparison). Within the anthracycline-treatment subgroup, the combined GRP78 and CHOP exhibited similar predictive significance. Cumulatively, our findings suggest a tight association between ER stress markers and clinical outcomes for patients with breast cancer.
机译:葡萄糖调节蛋白(GRP)78和C / -EBP同源蛋白(CHOP)通常用作内质网(ER)应激的标志物。作为ER分子伴侣,GRP78发挥有效的抗凋亡因子的作用并赋予药物抗药性,而CHOP是与ER应激相关的细胞死亡的关键启动因子。我们旨在研究GRP78和CHOP在接受辅助化疗的乳腺癌患者中的预测价值。在复旦大学上海癌症中心,使用组织微阵列对GRP78和CHOP进行了免疫组织化学筛选,该组织微阵列包含250位来自诊断为浸润性导管癌的女性患者的肿瘤。对染色结果进行半定量评分,并构建预测模型以验证该假设。在这项回顾性队列研究中,CHOP与无病生存期延长相关(HR = 0.385,95%CI 0.215-0.688; P = 0.001),而GRP78显示出相反的关联(HR = 4.573; 95%CI 2.291-9.128; P <0.001)。此外,在GRP78阳性子集中,CHOP过表达与较低的复发风险相关。在接收机工作特性分析中,结合了上述两个标记的预测模型的预测能力超过了传统模型的预测能力(曲线比较区域的P = 0.0085)。在蒽环类药物治疗亚组内,GRP78和CHOP的组合具有相似的预测意义。累积地,我们的发现表明,ER应激标志物与乳腺癌患者的临床结局之间有着紧密的联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号